Molecule News and Research

RSS

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%.

8 Jun 2015

PALOMA3 supports palbociclib use in advanced breast cancer

Advanced breast cancer patients who have failed prior endocrine treatment may receive a progression-free survival benefit if palbociclib is added to fulvestrant, a phase III trial indicates.

5 Jun 2015

$Elotuzumab boosts response in relapsed, refractory multiple myeloma$

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.

4 Jun 2015

New strategy involving three-pronged approach may keep lung cancer aside

Lung cancer is the leading cause of cancer death worldwide, responsible for some 1.59 million deaths a year. That figure is due, in part, to the fact that lung cancer often returns after what seems at first to be successful treatment. However, the recurring cancer is often resistant to the chemotherapy and other drugs that originally drove it into remission.

4 Jun 2015

Researchers discover new pathway that may be vital for understanding allergic asthma

Researchers at the Centenary Institute have discovered a new pathway that may be vital for our understanding allergic asthma, the most common form of asthma and the prevalent form of childhood-onset asthma affecting 2 million Australians.

3 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).

2 Jun 2015

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore.

2 Jun 2015

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Secret to the life-long activity of a stem cell niche

The roots of a plant are constantly growing, so that they can provide the plant with water and minerals while also giving it a firm anchor in the ground. Responsible for these functions are pluripotent stem cells. In order to avoid differentiation and to remain pluripotent, these stem cells are dependent on signals from their neighbouring cells.

1 Jun 2015

UH researchers identify new method to provide diagnostic information on kidney disease

University of Houston researchers have identified a new, less-invasive method to provide diagnostic information on kidney disease and its severity.

30 May 2015

UB researchers successfully harness E. coli to generate new forms of antibiotics

Like a dairy farmer tending to a herd of cows to produce milk, researchers are tending to colonies of the bacteria Escherichia coli (E. coli) to produce new forms of antibiotics -- including three that show promise in fighting drug-resistant bacteria.

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

MIT, UCSD researchers use probiotics to detect cancer in the liver

Engineers at MIT and the University of California at San Diego have devised a new way to detect cancer that has spread to the liver, by enlisting help from probiotics — beneficial bacteria similar to those found in yogurt.

29 May 2015

Researchers find weak spot in some antibiotic-resistant bacteria

Using a complex modeling program that helps analyze the physical dynamics of large, structurally complex protein molecules, a research team has made progress towards finding a weak spot in the architecture of a group of enzymes that are essential to antibiotic resistance in a number of bacteria.

29 May 2015

Sanford-Burnham, Takeda partner to develop new therapeutic targets for cardiovascular disease

Sanford-Burnham Medical Research Institute at Lake Nona today announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. of Japan to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure.

29 May 2015

Progression of different types of breast cancer influenced differently by tumor microenvironment

Our environment can have a major impact on how we develop, and it turns out it's no different for cancer cells. In work published today in Neoplasia, a team of researchers led by Associate Professor Mikala Egeblad at Cold Spring Harbor Laboratory found that two different mouse models of breast cancer progressed differently based on characteristics of the tumor microenvironment - the area of tissue in which the tumor is embedded.

28 May 2015

Molecule News and Research

Global RA treatment market expected to increase just over $19 billion by 2020

PALOMA3 supports palbociclib use in advanced breast cancer

Elotuzumab boosts response in relapsed, refractory multiple myeloma

New strategy involving three-pronged approach may keep lung cancer aside

Researchers discover new pathway that may be vital for understanding allergic asthma

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Secret to the life-long activity of a stem cell niche

UH researchers identify new method to provide diagnostic information on kidney disease

UB researchers successfully harness E. coli to generate new forms of antibiotics

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

MIT, UCSD researchers use probiotics to detect cancer in the liver

Researchers find weak spot in some antibiotic-resistant bacteria

Sanford-Burnham, Takeda partner to develop new therapeutic targets for cardiovascular disease

Progression of different types of breast cancer influenced differently by tumor microenvironment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News